EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts
Open Access
- 24 April 2008
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 123 (1), 209-216
- https://doi.org/10.1002/ijc.23488
Abstract
Malignant gliomas and childhood ependymomas have a high rate of treatment failure. Epidermal growth factor receptor (EGFR) activation has been implicated in the tumorigenesis and radioresistance of many cancers, including brain tumors. Therefore, combining EGFR targeting with irradiation is a potentially attractive therapeutic option. We evaluated the tyrosine kinase inhibitor gefitinib for its antitumor activity and potential to radio‐sensitize in vivo in two xenograft models: an EGFR amplified glioma and an EGFR expressing ependymoma, both derived from primary tumors. When administered at 100 mg/kg for 5 consecutive days, gefitinib‐induced partial tumor regression in all treated EGFR amplified IGRG88 glioma xenografts. The addition of 1 Gy of irradiation prior to gefitinib administration resulted in 5 complete and 4 partial regressions for the 9 treated tumors as well as a significant tumor growth delay of 33 days for the combined treatment compared to 19 days for each therapy alone, suggesting additive antitumor activity. Tumor regression was associated with inhibition of AKT and MAPK pathways by gefitinib. In contrast, the ependymoma IGREP83 was sensitive to irradiation, but remained resistant to gefitinib. Combined treatment was associated with inhibition of radiation‐induced MAPK phosphorylation and significant induction of apoptotic cell death though radiation‐induced AKT phosphorylation was maintained. Depending on the scheduling of both therapies, a trend towards superior antitumor activity was observed with combined treatment. Thus, EGFR targeting through tyrosine kinase inhibition appears to be a promising new approach in the treatment of EGFR‐driven glioma, particularly in combination with radiation therapy.Keywords
This publication has 27 references indexed in Scilit:
- Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular DomainPLoS Medicine, 2006
- Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma1Neuro-Oncology, 2006
- Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsNew England Journal of Medicine, 2005
- Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01Clinical Cancer Research, 2005
- p53 pathway dysfunction in primary childhood ependymomasPediatric Blood & Cancer, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumorsInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancerInternational Journal of Cancer, 2003
- Studies with ZD1839 in preclinical modelsSeminars in Oncology, 2003